Cover Image
市場調查報告書

歐洲帕金森氏症治療藥的開發平台分析

Europe Parkinson Disease Drug Pipeline Analysis

出版商 PNS Pharma 商品編碼 302557
出版日期 內容資訊 英文 199 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
歐洲帕金森氏症治療藥的開發平台分析 Europe Parkinson Disease Drug Pipeline Analysis
出版日期: 2014年01月14日 內容資訊: 英文 199 Pages
簡介

帕金森氏症是僅次於阿茲海默症的一般性神經退化性疾病。由於近年歐洲帕金森氏症發症率的增加,預測該傾向今後也將持續。最近的推計,歐洲有100萬人罹患帕金森氏症,一般預測該人數到2030年將膨漲到二倍。

本報告詳細調查在歐洲正在開發的各種帕金森氏症治療藥,為您概述為以下內容。

第1章 歐洲的帕金森氏症市場概要

第2章 帕金森氏症臨床開發階段:研究

  • 概要
  • 帕金森氏症治療藥臨床階段的簡介

第3章 帕金森氏症臨床開發階段:臨床試驗前

  • 概要
  • 帕金森氏症治療藥臨床階段的簡介

第4章 帕金森氏症臨床開發階段:臨床試驗

  • 概要
  • 帕金森氏症治療藥臨床階段的簡介

第5章 帕金森氏症臨床開發階段:階段I

  • 概要
  • 帕金森氏症治療藥臨床階段的簡介

第6章 帕金森氏症臨床開發階段:階段I/II

  • 概要
  • 帕金森氏症治療藥臨床階段的簡介

第7章 帕金森氏症臨床開發階段:階段II

  • 概要
  • 帕金森氏症治療藥臨床階段的簡介

第8章 帕金森氏症臨床開發階段:階段II/III

  • 概要
  • 帕金森氏症治療藥臨床階段的簡介

第9章 帕金森氏症臨床開發階段:階段III

  • 概要
  • 帕金森氏症治療藥臨床階段的簡介

第10章 帕金森氏症臨床開發階段:預備登記

  • 概要
  • 帕金森氏症治療藥臨床階段的簡介

第11章 上市

  • 概要
  • 已上市帕金森氏症治療藥
目錄

Parkinson's disease incidence has been on a rise in Europe in recent years and it most likely to continue rising in the near future. It has been estimated that currently, more than 1 million in Europe are affected by Parkinson's disease. This figure is most likely to double by 2030. Among the most common neurodegenerative disease (after Alzheimer's disease), Parkinson's is the second most common and it is expected that with ageing population, its prevalence would grow significantly.

One of the major drivers of the Parkinson's drugs market in the Europe is the rising uptake of key current brands along with the launch of three new therapies which would help sustain the Parkinson's disease market through 2022. However, growing competition from generics would continue to restrain the market in the future. Consequently, owing to competitive forces, the total sales of therapies used to treat the disease would remain relatively flat over the next decade.

"Europe Parkinson's Disease Drug Pipeline Analysis" by PNS Pharma gives comprehensive insight on the various drugs being developed for the treatment of Parkinson's disease. Research report covers all the ongoing drugs being developed in various development phases. This report enables pharmaceutical companies, collaborators and other associated stake holders to identify and analyze the available investment opportunity in the European Parkinson's Disease drug market based upon development process.

Following parameters for each drug profile in development phase are covered in "Europe Parkinson's Disease Drug Pipeline Analysis" research report:

  • Drug Profile Overview
  • Alternate Names for Drug
  • Active Indication
  • Phase of Development
  • Mechanism of Action
  • Brand Name
  • Patent Information
  • Country for Clinical Trial
  • Owner / Originator/ Licensee/Collaborator
  • Administrative Route
  • Drug Class
  • ATC Codes

Europe Parkinson's Disease Drug Pipeline by Clinical Phase:

  • Research: 12
  • Clinical: 26
  • Phase-I: 14
  • Phase-I/II: 2
  • Phase-II: 6
  • Phase-II/III: 1
  • Phase-III: 3
  • Preregistration: 1
  • Marketed: 18

Table of Contents

1. Europe Parkinson's Disease Drug Market Overview

2. Parkinson's Disease Clinical Development Phase: Research

  • 2.1. Overview
  • 2.2. Parkinson's Disease Drug Profile in Clinical Phase

3. Parkinson's Disease Clinical Development Phase: Preclinical

  • 3.1. Overview
  • 3.2. Parkinson's Disease Drug Profile in Clinical Phase

4. Parkinson's Disease Clinical Development Phase: Clinical

  • 4.1. Overview
  • 4.2. Parkinson's Disease Drug Profile in Clinical Phase

5. Parkinson's Disease Clinical Development Phase: Phase-I

  • 5.1. Overview
  • 5.2. Parkinson's Disease Drug Profile in Clinical Phase

6. Parkinson's Disease Clinical Development Phase: Phase-I/II

  • 6.1. Overview
  • 6.2. Parkinson's Disease Drug Profile in Clinical Phase

7. Parkinson's Disease Clinical Development Phase: Phase-II

  • 7.1. Overview
  • 7.2. Parkinson's Disease Drug Profile in Clinical Phase

8. Parkinson's Disease Clinical Development Phase: Phase-II/III

  • 8.1. Overview
  • 8.2. Parkinson's Disease Drug Profile in Clinical Phase

9. Parkinson's Disease Clinical Development Phase: Phase-III

  • 9.1. Overview
  • 9.2. Parkinson's Disease Drug Profile in Clinical Phase

10. Parkinson's Disease Clinical Development Phase: Preregistration

  • 10.1. Overview
  • 10.2. Parkinson's Disease Drug Profile in Clinical Phase

11. Marketed

  • 11.1. Overview
  • 11.2. Marketed Parkinson's Disease Drug

List of Table

Each Drug Profile has Tables Representing Following Information:

  • Alternate Names
  • Originator & Owner
  • Collaborator
  • Technology Provider
  • Licensee
  • Highest Development Phase
  • Indications
  • Class
  • Mechanism of Action
  • ATC Code
  • Designated Brand Name
Back to Top